Back

SET1B drives sustained HIF activity and disease progression in clear cell renal cell carcinoma.

Ortmann, B.; Bertlin, J. A. C.; Seear, R. V.; Arnaiz, E.; Lin, S.; Salman, A. M.; Wilson, L.; Harris, A. L.; Stewart, G. D.; Hepburn, A.; Clare, S.; Robson, C. N. N.; Speak, A. O.; Nathan, J. A.

2025-05-14 cancer biology
10.1101/2025.05.13.653699 bioRxiv
Show abstract

The cellular response to hypoxia is driven by hypoxia-inducible factors (HIFs), which regulate genes involved in glycolysis, angiogenesis, and cell proliferation, as well as inflammation and tumour progression. HIF activation is well-characterised and is primarily regulated by oxygen-dependent prolyl hydroxylation and subsequent degradation. However, how transcription of individual HIF target genes is regulated at the chromatin level is less clear. SET1B, a histone H3 lysine 4 (H3K4) methyltransferase, has emerged as a key modulator of HIF target gene transcription. Our study reveals that SET1B interacts with RNA Polymerase II to coordinate sustained HIF-mediated transcriptional activity through multiple functional domains. We also show that in clear cell renal cell carcinoma (ccRCC), SET1B is critical for sustained HIF activity, and SET1B expression correlates with disease progression and metastasis in patient samples. Moreover, SET1B depletion enhances the efficacy of HIF-2 inhibitors, establishing SET1B as a potential therapeutic target in ccRCC.

Published in Cancer Research (predicted rank #6) · training set

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.